Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study
Authors' conclusion
Since there is no difference in terms of follow-up parameters and outcomes, COVID-19- and SARS-CoV-2 vaccine-related SAT can be treated and followed up like classic SATs. Recurrence was determined by younger age and steroid therapy requirement. Steroid therapy independently predicts incident hypothyroidism that may sometimes be transient in overall SAT and is also associated with a lower risk of established hypothyroidism.
Study context
- Population
- Patients with subacute thyroiditis (SAT), 53 endocrinology centers in Turkey
- Participants
- 811 patients
- Exposure
- COVID-19-related SAT vs SARS-CoV-2 vaccine-related SAT vs control SAT
- Vac-SATn = 258
- Cov-SATn = 98
- Control SAT (Cont-SAT)n = 455reference
- Outcome
- SAT characteristics and predictors of recurrence and hypothyroidism by etiology
Methodological detailsnationwide, multicenter
- Nationwide
- Multicenter
Main finding
As reported in the abstract
- No difference between the groups in laboratory and imaging findings
- SAT etiology was not an independent predictor of recurrence or hypothyroidism
Observational data: associations, not effects.
Further findings
Predictors of SAT recurrence (entire cohort)
- Steroid therapy requirement and younger age were significant predictors of SAT recurrence
Predictors of incident (early) hypothyroidism
- C-reactive protein at SAT onset, female sex, absence of TPO positivity and absence of steroid therapy were significant predictors, irrespective of SAT etiology
Predictors of established hypothyroidism
- Probable predictors of established hypothyroidism differed from those of incident hypothyroidism
Original publication
Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study. J Clin Endocrinol Metab. Published 25 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →